These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
208 related items for PubMed ID: 26938766
1. Allele and Genotype Frequencies of Cytochrome P450 2B6 516G>T Single Nucleotide Polymorphism in HIV-Negative and HIV-Infected Adult Nigerian Populations. Saʼad Toyin A, Julius Olugbenga S, Rahman Ayodele B, Olusola Joseph O, Taibat Moji BO. Am J Ther; 2016; 23(6):e1715-e1719. PubMed ID: 26938766 [Abstract] [Full Text] [Related]
2. Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection. Peko SM, Gueye NSG, Vouvoungui C, Koukouikila-Koussounda F, Kobawila SC, Nderu D, Velavan TP, Ntoumi F. Int J Infect Dis; 2019 May; 82():111-116. PubMed ID: 30818046 [Abstract] [Full Text] [Related]
3. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P. Ann Hematol; 2011 Mar; 90(3):293-9. PubMed ID: 20878158 [Abstract] [Full Text] [Related]
4. Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy. Isaac AO, Wetkos DD, Oche AO, Godwin I, Phyllis K, John AC. Niger J Clin Pract; 2020 Dec; 23(12):1736-1743. PubMed ID: 33355828 [Abstract] [Full Text] [Related]
7. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, Khoo S, Back Dj, Owen A. HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205 [Abstract] [Full Text] [Related]
8. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya. Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA. PLoS One; 2022 May; 17(3):e0260872. PubMed ID: 35235559 [Abstract] [Full Text] [Related]
10. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Chaivichacharn P, Avihingsanon A, Manosuthi W, Ubolyam S, Tongkobpetch S, Shotelersuk V, Punyawudho B. Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120 [Abstract] [Full Text] [Related]
12. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico. Ortíz-Rodríguez MA, Oaxaca-Navarro J, Patiño-Camacho SI, García-Jiménez S, Déciga-Campos M, Martínez-Salazar MF. Pharmazie; 2022 Jun 01; 77(6):191-195. PubMed ID: 35751161 [Abstract] [Full Text] [Related]
14. Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples. Weber A, Szalai R, Sipeky C, Magyari L, Melegh M, Jaromi L, Matyas P, Duga B, Kovesdi E, Hadzsiev K, Melegh B. Pharmacol Rep; 2015 Jun 01; 67(3):460-4. PubMed ID: 25933954 [Abstract] [Full Text] [Related]
18. Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz. Mardi P, Tavakoli-Far B, Sheibani Nia S, Jazayeri R, Houshmand M. Genet Res (Camb); 2022 Jun 01; 2022():5754776. PubMed ID: 36320932 [Abstract] [Full Text] [Related]